Levonadifloxacin

• CAT Number: M098888
• CAS Number: 154357-42-3
• Molecular Formula: C19H21FN2O4
• Molecular Weight: 360.38
• Purity: ≥95%
• Synonyms: (12S)-7-fluoro-8-(4-hydroxypiperidin-1-yl)-12-methyl-4-oxo-1-azatricyclo[7.3.1.05,13]trideca-2,5,7,9(13)-tetraene-3-carboxylic acid
• InChI: InChI=1S/C19H21FN2O4/c1-10-2-3-12-16-13(18(24)14(19(25)26)9-22(10)16)8-15(20)17(12)21-6-4-11(23)5-7-21/h8-11,23H,2-7H2,1H3,(H,25,26)/t10-/m0/s1
• InChIKey: JYJTVFIEFKZWCJ-JTQLQIEISA-N
• SMILES: CC1CCC2=C3N1C=C(C(=O)C3=CC(=C2N4CCC(CC4)O)F)C(=O)O

Levonadifloxacin (Cat No.: M098888) is a novel broad-spectrum antibiotic belonging to the benzoquinolizine subclass of fluoroquinolones. It exhibits potent activity against Gram-positive bacteria, including multidrug-resistant strains like methicillin-resistant Staphylococcus aureus (MRSA). Levonadifloxacin works by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes for DNA replication. Available in both oral and intravenous formulations, it is used to treat acute bacterial skin and soft tissue infections (ABSSSI) and other serious infections. Its efficacy and safety profile make it a valuable option in antimicrobial therapy.

Reference

[1]. Dubois J, et al. Levonadifloxacin (WCK 771) exerts potent intracellular activity against Staphylococcus aureus in THP-1 monocytes at clinically relevant concentrations. J Med Microbiol. 2019 Dec;68(12):1716-1722.
[Content Brief]

[2]. Bhagwat SS, et al. In Vivo Pharmacokinetic/Pharmacodynamic Targets of Levonadifloxacin against Staphylococcus aureus in a Neutropenic Murine Lung Infection Model. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00909-19.
[Content Brief]